Drugmakers AbbVie and Boehringer Ingelheim (BI) have agreed in principle to exempt Arkansas providers from their 340B contract pharmacy restrictions, [...] …
Blog Posts
A key New York senator has introduced legislation that would bar pharmaceutical manufacturers and pharmacy benefit managers (PBMs) from discriminating [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Merck has added an injectable medication used to treat pulmonary arterial hypertension—a type of high blood pressure which affects the [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Federal regulators recently said any decision on whether to provide Medicare Advantage (MA) plans funds to reimburse hospitals for past [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Supporters recently submitted enough signatures to qualify for the ballot a California ballot initiative that aims to codify the governor’s [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Breaking News
HRSA Issues Final Regulations Revamping Process to Resolve Disputes Between 340B Providers and Manufacturers
The federal government issued the final rule early Thursday to implement a long-anticipated revision to the 340B Administrative Dispute Resolution [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
SPONSORED CONTENT
TIP: When updating your 340B program policies and procedures, prioritize clear communication and training to ensure staff compliance and minimize errors.
Virginia legislators will soon act on Gov. Glenn Youngkin’s (R) proposed amendment to a 340B contract pharmacy access bill when [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Advocates for Mississippi hospitals and health centers praised the recent enactment of a law to prohibit drugmaker 340B contract pharmacy [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
SPONSORED CONTENT
Since 2020, select drug manufacturers have begun deploying restrictions or limitations on the sale of their products through the 340B program. This has proven to be a marketplace disruptor that has shifted the landscape of the 340B contract pharmacy program, as covered entities have experienced a loss of savings and have had to increasingly rely on entity-owned retail and/or specialty pharmacy operations to help in their mission. The issue of manufacturer restrictions has endured several legal challenges as well with some states, such as Arkansas, Louisiana, West Virginia and Mississippi having measurable success with combating the manufacturer restrictions.
Regardless, manufacturers continue to impose restrictions with the assistance of 340B ESP, a drug industry vendor that facilitates 340B claim management and oversees implementation of drug maker policies. In many cases, the restrictions made by the manufacturers will be applied to the covered entity for all contract pharmacies unless the covered entity has created
…
×
*Sign up for news summaries and alerts from 340B Report